HO-1hipatrolling monocytes protect against vaso-occlusion in sickle cell disease

Publication Date

2018

Journal Title

Blood

Abstract

© 2018 by The American Society of Hematology. Patients with sickle cell disease (SCD) suffer from intravascular hemolysis associated with vascular injury and dysfunction in mouse models, and painful vaso-occlusive crisis (VOC) involving increased attachment of sickle erythrocytes and activated leukocytes to damaged vascular endothelium. Patrolling monocytes, which normally scavenge damaged cells and debris from the vasculature, express higher levels of anti-inflammatory heme oxygenase 1 (HO-1), a heme degrading enzyme. Here, we show that HO-1–expressing patrolling monocytes protect SCD vasculature from ongoing hemolytic insult and vaso-occlusion. We found that a mean 37% of patrolling monocytes from SCD patients express very high levels of HO-1 (HO-1hi) vs 6% in healthy controls and demonstrated that HO-1hiexpression was dependent on uptake of heme-exposed endothelium. SCD patients with a recent VOC episode had lower numbers of HO-1hipatrolling monocytes. Heme-mediated vaso-occlusion by mouse SCD red blood cells was exacerbated in mice lacking patrolling monocytes, and reversed following transfer of patrolling monocytes. Altogether, these data indicate that SCD patrolling monocytes remove hemolysis-damaged endothelial cells, resulting in HO-1 upregulation and dampening of VOC, and that perturbation in patrolling monocyte numbers resulting in lower numbers of HO-1hipatrolling monocyte may predispose SCD patients to VOC. These data suggest that HO-1hipatrolling monocytes are key players in VOC pathophysiology and have potential as therapeutic targets for VOC.

Volume Number

131

Issue Number

14

Pages

1600 - 1610

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Cardiology

PMID

29437594

DOI

10.1182/blood-2017-12-819870

For the public and Northwell Health campuses

Share

COinS